Our Pricing

Higher Wegovy Doses & Weight Loss - All Doses Available

Published on: June 03, 2026

Understanding higher dose Wegovy weight loss UK outcomes helps you set realistic expectations for your treatment journey. At Cured Pharmacy, all Wegovy dose strengths are available from £79.00 with transparent pricing shown before your free clinical consultation with a UK-registered prescriber.

How Higher Wegovy Doses Affect Weight Loss

Wegovy (semaglutide) demonstrates a clear dose-dependent relationship with weight loss outcomes in clinical trials [1]. The STEP 1 trial showed that participants receiving the maximum 2.4mg weekly dose achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Lower maintenance doses produced correspondingly smaller reductions, confirming that higher doses generally correlate with greater weight loss.

This dose-response relationship occurs because semaglutide works by activating GLP-1 receptors in the brain and digestive system, reducing appetite and slowing gastric emptying [2]. Higher circulating levels of the medication produce stronger receptor activation, leading to more pronounced effects on satiety and food intake. However, individual responses vary based on metabolic factors, adherence, and lifestyle modifications alongside treatment.

Wegovy Dose Escalation Schedule in the UK

UK prescribers follow a structured dose escalation protocol to minimise gastrointestinal side effects whilst building towards the therapeutic 2.4mg maintenance dose [3]. The standard schedule begins with 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg before reaching the final 2.4mg dose at week 17.

This gradual titration allows your digestive system to adapt to semaglutide's effects on gastric motility and reduces the likelihood of nausea, vomiting, and diarrhoea [3]. Some patients may require slower progression if they experience persistent side effects at lower doses. Your UK prescriber will monitor your tolerance and adjust the escalation timeline accordingly, ensuring you reach the highest tolerable dose safely.

What If Side Effects Prevent Dose Increases?

If gastrointestinal symptoms persist at a particular dose level, your prescriber may recommend staying at that strength for an additional four weeks before attempting escalation. Clinical evidence shows that many patients achieve meaningful weight loss on sub-maximal doses, with the 1.7mg dose producing substantial results in those unable to tolerate 2.4mg [1]. The goal is always the highest dose you can maintain comfortably alongside dietary and activity modifications.

Clinical Trial Data: Weight Loss by Wegovy Dose

The landmark STEP clinical trial programme evaluated semaglutide across multiple dose strengths in over 4,500 participants [1][4]. In STEP 1, participants on 2.4mg weekly lost an average 14.9% of baseline body weight, whilst those on 1.7mg in other study arms achieved approximately 11-13% reductions. Lower doses used during titration periods showed progressively smaller effects, confirming the dose-dependent nature of semaglutide's weight loss properties.

Importantly, these averages mask significant individual variation. In the STEP trials, approximately one-third of participants on the maximum dose achieved weight loss exceeding 20% of baseline body weight, whilst others experienced more modest reductions [1]. Factors including baseline BMI, adherence to lifestyle interventions, genetic variations in GLP-1 receptor expression, and concurrent medications all influence individual outcomes beyond dose alone.

Real-World Outcomes vs Clinical Trials

Post-marketing surveillance and real-world evidence studies suggest that average weight loss in routine clinical practice may be slightly lower than controlled trial results, typically ranging from 10-15% at the 2.4mg maintenance dose [4]. This reflects differences in adherence, lifestyle support intensity, and patient selection compared to trial populations. Your UK prescriber will discuss realistic expectations based on your individual circumstances during your clinical assessment.

Comparing Higher Dose Wegovy to Other Weight Loss Treatments

Wegovy at the 2.4mg maintenance dose represents one of the most effective pharmacological weight loss treatments currently licensed in the UK by the MHRA. Compared to earlier GLP-1 receptor agonists like liraglutide (Saxenda), semaglutide produces approximately 50% greater weight reduction at comparable treatment durations [2]. The once-weekly injection schedule also improves adherence compared to daily injectable alternatives.

Newer dual GIP/GLP-1 receptor agonists show even greater efficacy in head-to-head comparisons, with average weight reductions approaching 20-22% in clinical trials [5]. However, these treatments are not yet as widely available through UK online pharmacies, and cost considerations may influence treatment selection. Your prescriber will help you weigh the clinical benefits, side effect profiles, and practical factors when choosing the most appropriate option for your weight management goals.

Who Can Access Higher Wegovy Doses in the UK

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. All patients who meet these criteria and have no contraindications can potentially escalate to the full 2.4mg maintenance dose, subject to tolerability and prescriber assessment.

Certain medical conditions preclude Wegovy use entirely, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease [3]. Your UK prescriber will review your complete medical history, current medications, and weight loss goals during your clinical consultation to determine whether Wegovy is appropriate and which dose escalation schedule suits your individual circumstances. All prescription medications at Cured Pharmacy require this clinical assessment by a UK-registered prescriber before dispensing.

Accessing All Wegovy Doses at Cured Pharmacy

Cured Pharmacy stocks all Wegovy dose strengths—0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg—ensuring continuity throughout your dose escalation journey. Our transparent pricing model shows costs upfront before your consultation, and our UK clinical team completes assessments within three minutes. Once approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), with discreet next-day delivery across the UK.

Maximising Weight Loss on Higher Wegovy Doses

Clinical trial data consistently shows that participants who combine Wegovy with structured lifestyle interventions achieve significantly greater weight loss than those relying on medication alone [1][4]. The STEP 1 trial included a 500-calorie daily deficit diet and 150 minutes of weekly physical activity, creating the conditions for the observed 14.9% average weight reduction. Without these behavioural modifications, weight loss outcomes diminish substantially even at the maximum 2.4mg dose.

Practical strategies include prioritising protein intake to preserve lean muscle mass during weight loss, increasing non-starchy vegetables for satiety and micronutrients, and incorporating resistance training to maintain metabolic rate [4]. Adequate hydration becomes particularly important on higher Wegovy doses, as the medication's effects on gastric emptying can reduce thirst perception whilst gastrointestinal side effects increase fluid loss. Your prescriber may recommend working with a registered dietitian or weight management programme to optimise your results alongside pharmacological treatment.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. UK Public Assessment Report. [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.